NASDAQ:OMER - Omeros Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.25
  • Forecasted Upside: 81.01 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$11.74
▲ +0.03 (0.26%)
1 month | 3 months | 12 months
Get New Omeros Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OMER and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OMER

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$21.25
▲ +81.01% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Omeros in the last 3 months. The average price target is $21.25, with a high forecast of $32.00 and a low forecast of $12.00. The average price target represents a 81.01% upside from the last price of $11.74.
Buy
The current consensus among 5 polled investment analysts is to buy stock in Omeros. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/8/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/6/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/5/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/4/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/2/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/31/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/30/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/29/2020

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/23/2020HC WainwrightReiterated RatingBuy$32.00Medium
i
10/20/2020Bank of AmericaInitiated CoverageBuy$21.00High
i
9/1/2020WedbushLower Price TargetNeutral$17.00 ➝ $12.00High
i
Rating by Liana Moussatos at Wedbush
8/21/2020HC WainwrightLower Price TargetBuy$34.00 ➝ $32.00High
i
Rating by Ram Selvaraju at HC Wainwright
8/14/2020Maxim GroupLower Price TargetBuy$25.00 ➝ $20.00Low
i
6/9/2020WedbushReiterated RatingHold$17.00Medium
i
Rating by Liana Moussatos at Wedbush
5/12/2020Needham & Company LLCReiterated RatingHoldHigh
i
5/12/2020HC WainwrightReiterated RatingBuy$34.00High
i
Rating by Ram Selvaraju at HC Wainwright
4/27/2020WedbushReiterated RatingHold$17.00Low
i
Rating by Liana Moussatos at Wedbush
3/4/2020WedbushReiterated RatingHold$18.00 ➝ $22.00Medium
i
Rating by Liana Moussatos at Wedbush
3/3/2020HC WainwrightReiterated RatingBuy$34.00N/A
i
Rating by Ram Selvaraju at HC Wainwright
12/5/2019Maxim GroupReiterated RatingBuy$25.00Low
i
Rating by Jason McCarthy at Maxim Group
12/4/2019Needham & Company LLCReiterated RatingHoldHigh
i
12/2/2019HC WainwrightReiterated RatingBuy$35.00 ➝ $34.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
11/15/2019WedbushReiterated RatingHold$18.00Low
i
Rating by Liana Moussatos at Wedbush
11/13/2019Needham & Company LLCReiterated RatingHoldLow
i
11/5/2019HC WainwrightReiterated RatingBuy$35.00High
i
Rating by Ram Selvaraju at HC Wainwright
10/30/2019HC WainwrightReiterated RatingBuy$35.00High
i
Rating by Ram Selvaraju at HC Wainwright
10/28/2019WedbushReiterated RatingHold$18.00Low
i
Rating by Liana Moussatos at Wedbush
9/18/2019HC WainwrightSet Price TargetBuy$35.00Low
i
Rating by Ram Selvaraju at HC Wainwright
8/9/2019Maxim GroupSet Price TargetBuy$32.00High
i
Rating by Jason McCarthy at Maxim Group
7/15/2019WedbushReiterated RatingNeutral$18.00Medium
i
Rating by L. Moussatos at Wedbush
5/28/2019HC WainwrightSet Price TargetBuy$35.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
5/20/2019WedbushReiterated RatingHold$18.00Medium
i
Rating by L. Moussatos at Wedbush
5/6/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$26.00Low
i
3/4/2019HC WainwrightReiterated RatingBuy$35.00High
i
Rating by Ram Selvaraju at HC Wainwright
12/13/2018HC WainwrightSet Price TargetBuy$34.00High
i
Rating by Ram Selvaraju at HC Wainwright
12/6/2018Maxim GroupSet Price TargetBuy$32.00Medium
i
Rating by Jason McCarthy at Maxim Group
12/4/2018HC WainwrightReiterated RatingBuy$34.00High
i
Rating by Ram Selvaraju at HC Wainwright
11/9/2018Maxim GroupReiterated RatingBuy$32.00High
i
Rating by Jason McCarthy at Maxim Group
10/24/2018HC WainwrightSet Price TargetBuy$34.00High
i
Rating by Ram Selvaraju at HC Wainwright
10/15/2018HC WainwrightSet Price TargetBuy$34.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
8/29/2018HC WainwrightSet Price TargetBuy$34.00Low
i
Rating by Ram Selvaraju at HC Wainwright
8/28/2018Maxim GroupReiterated RatingBuy$32.00Low
i
Rating by Jason McCarthy at Maxim Group
8/10/2018WedbushSet Price TargetHold$20.00High
i
Rating by Liana Moussatos at Wedbush
8/10/2018Maxim GroupBoost Price TargetBuy ➝ Buy$25.00 ➝ $32.00N/A
i
Rating by Jason McCarthy at Maxim Group
8/6/2018HC WainwrightSet Price TargetBuy$34.00Low
i
Rating by Ram Selvaraju at HC Wainwright
7/24/2018HC WainwrightSet Price TargetBuy$34.00High
i
Rating by Ram Selvaraju at HC Wainwright
7/18/2018HC WainwrightSet Price TargetBuy$34.00Low
i
Rating by Ram Selvaraju at HC Wainwright
7/12/2018Seaport Global SecuritiesInitiated CoverageBuy$30.00High
i
Rating by C. Davis at Seaport Global Securities
6/28/2018HC WainwrightReiterated RatingBuy$34.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
5/25/2018HC WainwrightSet Price TargetBuy$34.00Low
i
Rating by Ram Selvaraju at HC Wainwright
5/16/2018WedbushReiterated RatingNeutral ➝ Hold$19.00 ➝ $20.00Low
i
Rating by L. Moussatos at Wedbush
5/13/2018Maxim GroupSet Price TargetBuy$25.00High
i
Rating by Jason McCarthy at Maxim Group
5/11/2018HC WainwrightSet Price TargetBuy$34.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/7/2018Maxim GroupReiterated RatingBuy$25.00Medium
i
Rating by Jason McCarthy at Maxim Group
5/3/2018HC WainwrightSet Price TargetBuy$34.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
4/4/2018HC WainwrightSet Price TargetBuy$34.00High
i
Rating by Ram Selvaraju at HC Wainwright
3/26/2018WBB SecuritiesReiterated RatingBuy$75.00High
i
3/23/2018HC WainwrightReiterated RatingBuy$34.00High
i
Rating by Ram Selvaraju at HC Wainwright
3/23/2018WedbushDowngradeOutperform ➝ Neutral$47.00 ➝ $19.00High
i
Rating by L. Moussatos at Wedbush
3/22/2018Maxim GroupBoost Price TargetBuy ➝ Buy$24.00 ➝ $25.00Medium
i
Rating by Jason McCarthy at Maxim Group
3/5/2018HC WainwrightSet Price TargetBuy$30.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
3/2/2018Needham & Company LLCDowngradeBuy ➝ Hold$9.01High
i
Rating by Serge Belanger at Needham & Company LLC
3/2/2018Maxim GroupSet Price TargetBuy$24.00High
i
Rating by Jason Kolbert at Maxim Group
3/1/2018Cantor FitzgeraldSet Price TargetHold$19.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
2/19/2018HC WainwrightSet Price TargetBuy$30.00Low
i
Rating by Ram Selvaraju at HC Wainwright
2/15/2018Maxim GroupSet Price TargetBuy$24.00Medium
i
Rating by Jason Kolbert at Maxim Group
2/14/2018Bank of AmericaBoost Price Target$2.44 ➝ $4.00Low
i
1/23/2018HC WainwrightSet Price TargetBuy$30.00Low
i
Rating by Ram Selvaraju at HC Wainwright
1/22/2018Maxim GroupSet Price TargetBuy$24.00Low
i
Rating by Jason Kolbert at Maxim Group
1/4/2018HC WainwrightSet Price TargetBuy$30.00Low
i
Rating by Ram Selvaraju at HC Wainwright
1/3/2018Maxim GroupSet Price TargetBuy$24.00Low
i
Rating by Jason Kolbert at Maxim Group
12/14/2017HC WainwrightSet Price TargetBuy$30.00Low
i
Rating by Ram Selvaraju at HC Wainwright
12/12/2017Maxim GroupSet Price TargetBuy$24.00High
i
Rating by Jason Kolbert at Maxim Group
11/29/2017HC WainwrightSet Price TargetBuy$30.00High
i
Rating by R. Selvaraju at HC Wainwright
11/28/2017WedbushReiterated RatingOutperform$47.00High
i
11/8/2017HC WainwrightInitiated CoverageBuy$30.00N/A
i
Rating by R. Selvaraju at HC Wainwright
11/6/2017Maxim GroupReiterated RatingBuy$24.00N/A
i
Rating by Jason Kolbert at Maxim Group
11/2/2017CowenDowngradeOutperform ➝ Market PerformN/A
i
10/27/2017Maxim GroupReiterated RatingBuy$24.00N/A
i
Rating by Jason Kolbert at Maxim Group
10/20/2017Maxim GroupSet Price TargetBuy$24.00N/A
i
Rating by Jason Kolbert at Maxim Group
8/24/2017Cantor FitzgeraldReiterated RatingHold$15.00 ➝ $19.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
8/18/2017WedbushReiterated RatingOutperform$47.00Low
i
8/8/2017Maxim GroupReiterated RatingBuy$23.00 ➝ $24.00High
i
Rating by Jason Kolbert at Maxim Group
8/2/2017Maxim GroupSet Price TargetBuy$23.00 ➝ $24.00Medium
i
Rating by Jason Kolbert at Maxim Group
6/14/2017WBB SecuritiesReiterated RatingStrong-Buy$75.00High
i
6/14/2017WedbushReiterated RatingOutperform$47.00High
i
6/13/2017Maxim GroupSet Price TargetBuy$23.00High
i
Rating by Jason McCarthy at Maxim Group
6/13/2017Cantor FitzgeraldSet Price TargetHold$15.00High
i
Rating by E. Piros at Cantor Fitzgerald
6/3/2017CowenReiterated RatingOutperformMedium
i
5/22/2017Maxim GroupSet Price TargetBuy$22.00 ➝ $23.00Low
i
Rating by Jason Kolbert at Maxim Group
5/11/2017Maxim GroupSet Price TargetBuy$23.00High
i
Rating by Jason Kolbert at Maxim Group
5/11/2017Cantor FitzgeraldDowngradeBuy ➝ Neutral$21.00 ➝ $15.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
5/10/2017WedbushReiterated RatingOutperform$47.00Low
i
4/3/2017WedbushReiterated RatingOutperform$47.00Low
i
4/1/2017FBR & CoReiterated RatingBuyLow
i
Rating by Thomas Yip at FBR & Co
3/30/2017WBB SecuritiesReiterated RatingBuy$75.00Medium
i
3/27/2017Maxim GroupReiterated RatingBuy ➝ Buy$22.00High
i
Rating by Jason Kolbert at Maxim Group
3/20/2017CowenReiterated RatingOutperformHigh
i
3/17/2017Cantor FitzgeraldReiterated RatingOverweight$21.00High
i
3/17/2017Maxim GroupReiterated RatingBuy ➝ Buy$19.00 ➝ $22.00High
i
Rating by Jason Kolbert at Maxim Group
3/17/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$24.00 ➝ $22.00High
i
3/11/2017Maxim GroupSet Price TargetBuy$19.00Medium
i
Rating by Jason Kolbert at Maxim Group
3/2/2017FBR & CoReiterated RatingBuyN/A
i
Rating by Thomas Yip at FBR & Co
3/1/2017Maxim GroupReiterated RatingBuyN/A
i
Rating by Jason Kolbert at Maxim Group
2/21/2017WedbushReiterated RatingOutperform$47.00N/A
i
2/8/2017WedbushReiterated RatingOutperform$47.00N/A
i
1/5/2017WedbushReiterated RatingOutperform$47.00N/A
i
12/5/2016UBS GroupReiterated RatingReduceN/A
i
11/17/2016WBB SecuritiesReiterated RatingBuy$75.00N/A
i
Rating by Stephen Brozak at WBB Securities
11/16/2016WedbushLower Price TargetOutperform$56.00 ➝ $47.00N/A
i
11/11/2016Cantor FitzgeraldReiterated RatingBuy$21.00N/A
i
Rating by Elemer Piros at Cantor Fitzgerald
11/10/2016FBR & CoReiterated RatingBuyN/A
i
Rating by Thomas Yip at FBR & Co
11/10/2016Needham & Company LLCLower Price TargetBuy$28.00 ➝ $24.00N/A
i
11/2/2016Maxim GroupSet Price TargetBuy$19.00N/A
i
Rating by Jason Kolbert at Maxim Group
10/21/2016WedbushReiterated RatingOutperform$56.00N/A
i
10/18/2016FBR & CoReiterated RatingOutperform$38.00N/A
i
Rating by Thomas Yip at FBR & Co
10/18/2016Maxim GroupReiterated RatingBuy$19.00N/A
i
Rating by Jason Kolbert at Maxim Group
10/17/2016Cantor FitzgeraldReiterated RatingBuy$21.00N/A
i
Rating by Elemer Piros at Cantor Fitzgerald
10/17/2016WBB SecuritiesReiterated RatingBuy$75.00N/A
i
Rating by Stephen Brozak at WBB Securities
10/17/2016S&P Equity ResearchBoost Price Target$7.65 ➝ $8.63N/A
i
8/11/2016WedbushReiterated RatingOutperform$62.00 ➝ $56.00N/A
i
8/10/2016Cantor FitzgeraldReiterated RatingBuy$21.00N/A
i
Rating by Elemer Piros at Cantor Fitzgerald
8/10/2016Maxim GroupLower Price TargetBuy$30.00 ➝ $19.00N/A
i
Rating by Jason Kolbert at Maxim Group
7/28/2016Maxim GroupReiterated RatingBuy$30.00N/A
i
Rating by Jason Kolbert at Maxim Group
6/29/2016FBR & CoReiterated RatingOutperform$38.00N/A
i
6/14/2016WBB SecuritiesReiterated RatingBuy$75.00N/A
i
6/4/2016Maxim GroupInitiated CoverageBuyN/A
i
Rating by Jason Kolbert at Maxim Group
6/2/2016Cantor FitzgeraldInitiated CoverageBuy$21.00N/A
i
Rating by E. Piros at Cantor Fitzgerald
5/19/2016Maxim GroupReiterated RatingBuy$30.00N/A
i
Rating by Jason Kolbert at Maxim Group
5/10/2016Maxim GroupReiterated RatingBuyN/A
i
Rating by Jason Kolbert at Maxim Group
5/10/2016WedbushReiterated RatingOutperform$62.00N/A
i
4/20/2016Maxim GroupReiterated RatingBuyN/A
i
Rating by Jason McCarthy at Maxim Group
3/9/2016Maxim GroupReiterated RatingBuy$30.00N/A
i
Rating by Jason McCarthy at Maxim Group
3/8/2016WedbushReiterated RatingOutperform$62.00N/A
i
3/2/2016Needham & Company LLCLower Price TargetBuy$30.00 ➝ $28.00N/A
i
Rating by Serge Belanger at Needham & Company LLC
2/29/2016WedbushLower Price TargetOutperform$65.00 ➝ $62.00N/A
i
2/24/2016Maxim GroupReiterated RatingBuy$30.00N/A
i
1/4/2016WedbushReiterated RatingOutperform$65.00N/A
i
Rating by Liana Moussatos at Wedbush
(Data available from 11/29/2015 forward)
Omeros logo
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that is in Phase III clinical trial for hematopoietic stem-cell transplant-associated thrombotic microangiopath, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consists of PPAR? (OMS405) that is in Phase II clinical trial to treat opioid and nicotine addiction; and PDE7 (OMS527), which is in Phase I clinical trial for treating addiction and compulsive disorders, and movement disorders. In addition, the company's preclinical programs comprise MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders; MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Further, its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular (CV), musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $11.74
$11.66
$11.97

50 Day Range

MA: $11.07
$10.14
$11.94

52 Week Range

Now: $11.74
$8.50
$25.46

Volume

215,065 shs

Average Volume

890,761 shs

Market Capitalization

$723.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.64